What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development

The Top Line

This week on “The Top Line,” we discuss two studies in HIV research that were presented at the 25th International AIDS Conference in Germany.

One of them is the report of a 7th person who has likely been cured of HIV. And there’s something unique about this case that has sparked excitement among scientists.

The other one is the report of a long-acting injection that showed 100% efficacy in preventing HIV infection in a phase 3 trial. Some experts have hailed the PrEP candidate as a game-changer.

To dive deeper into these studies, Fierce Pharma’s Angus Liu interviews Jared Baeten, M.D., Ph.D., senior vice president and head of clinical development of the virology therapeutic area at Gilead Sciences.

To learn more about the topics in this episode:

• With seventh person seemingly cured of HIV, signs of hope for a broader cure

• Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

See omnystudio.com/listener for privacy information.